Business Description
Enanta Pharmaceuticals Inc
NAICS : 325412
SIC : 2835
ISIN : US29251M1062
Total Employee Number:
120Description
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.9 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | -1.21 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.57 | |||||
Beneish M-Score | 3.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.9 | |||||
3-Year EBITDA Growth Rate | 16.7 | |||||
3-Year EPS without NRI Growth Rate | 13.4 | |||||
3-Year FCF Growth Rate | 29 | |||||
3-Year Book Growth Rate | -41.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -2.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.23 | |||||
9-Day RSI | 38.38 | |||||
14-Day RSI | 45.35 | |||||
3-1 Month Momentum % | -19.67 | |||||
6-1 Month Momentum % | -13.27 | |||||
12-1 Month Momentum % | 76.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.84 | |||||
Quick Ratio | 3.84 | |||||
Cash Ratio | 3.53 | |||||
Days Sales Outstanding | 40.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | -18.83 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -87.24 | |||||
Net Margin % | -89.56 | |||||
EBITDA Margin % | -67.26 | |||||
FCF Margin % | -13.52 | |||||
OCF Margin % | -10.98 | |||||
ROE % | -64.47 | |||||
ROA % | -20.01 | |||||
ROIC % | -44.87 | |||||
3-Year ROIIC % | 361.13 | |||||
ROC (Joel Greenblatt) % | -70.46 | |||||
ROCE % | -19.52 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.68 | |||||
PB Ratio | 3.27 | |||||
Price-to-Tangible-Book | 3.27 | |||||
EV-to-EBIT | -5.32 | |||||
EV-to-EBITDA | -5.89 | |||||
EV-to-Revenue | 3.96 | |||||
EV-to-Forward-Revenue | 4.28 | |||||
EV-to-FCF | -28.51 | |||||
Price-to-GF-Value | 1.49 | |||||
Price-to-Median-PS-Value | 0.67 | |||||
Earnings Yield (Greenblatt) % | -18.8 | |||||
FCF Yield % | -2.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Enanta Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 59.504 | ||
| EPS (TTM) (€) | -2.226 | ||
| Beta | 1.3044 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 88.06 | ||
| 14-Day RSI | 45.35 | ||
| 14-Day ATR (€) | 0.54882 | ||
| 20-Day SMA (€) | 12.165 | ||
| 12-1 Month Momentum % | 76.58 | ||
| 52-Week Range (€) | 5.45 - 14 | ||
| Shares Outstanding (Mil) | 29.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enanta Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enanta Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-11-19 | In 126 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-17 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-08-10 | In 25 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 9.60 (-4.95%) | ||
| Second quarter earnings results for 2026 | 2026-05-11 | 12.90 (+2.38%) | ||
| General meeting for 2026 | 2026-03-11 17:00 | 11.80 (+0.00%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 10:45 | 11.90 (+3.48%) | ||
| First quarter earnings results for 2026 | 2026-02-09 | 11.30 (+4.63%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-14 15:00 | 11.10 (+2.78%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-03 08:20 | 11.90 (+0.00%) |
Show
Entries
Enanta Pharmaceuticals Inc Frequently Asked Questions
What is Enanta Pharmaceuticals Inc(STU:9EP)'s stock price today?
The current price of STU:9EP is €11.50. The 52 week high of STU:9EP is €14.00 and 52 week low is €5.45.
When is next earnings date of Enanta Pharmaceuticals Inc(STU:9EP)?
The next earnings date of Enanta Pharmaceuticals Inc(STU:9EP) is 2026-08-10.
Does Enanta Pharmaceuticals Inc(STU:9EP) pay dividends? If so, how much?
Enanta Pharmaceuticals Inc(STU:9EP) does not pay dividend.
Press Release
Articles on Enanta Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers